Moderna (NASDAQ:MRNA) Price Target Raised to $163.00 at Oppenheimer

Moderna (NASDAQ:MRNA) had its price target boosted by Oppenheimer from $142.00 to $163.00 in a report published on Friday, Benzinga reports. The firm currently has an outperform rating on the stock.

Other equities analysts have also issued research reports about the stock. Needham & Company LLC reiterated a hold rating on shares of Moderna in a research report on Thursday, May 2nd. William Blair reiterated a market perform rating on shares of Moderna in a research report on Monday, April 1st. Jefferies Financial Group reiterated a buy rating and set a $125.00 target price on shares of Moderna in a research report on Tuesday, April 9th. Royal Bank of Canada reissued an outperform rating and issued a $125.00 price target on shares of Moderna in a report on Thursday, March 28th. Finally, Canaccord Genuity Group increased their price target on shares of Moderna from $82.00 to $91.00 and gave the stock a hold rating in a report on Friday, February 23rd. Two equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of Hold and a consensus target price of $129.55.

Moderna Price Performance

MRNA opened at $122.13 on Friday. The company has a debt-to-equity ratio of 0.04, a quick ratio of 3.91 and a current ratio of 4.03. The firm has a market cap of $46.81 billion, a P/E ratio of -7.79 and a beta of 1.57. Moderna has a fifty-two week low of $62.55 and a fifty-two week high of $142.79. The firm has a 50-day moving average of $105.61 and a 200 day moving average of $94.76.

Moderna (NASDAQ:MRNA) last issued its earnings results on Thursday, May 2nd. The company reported ($3.07) earnings per share for the quarter, topping analysts’ consensus estimates of ($3.59) by $0.52. The firm had revenue of $167.00 million during the quarter, compared to analyst estimates of $93.26 million. Moderna had a negative net margin of 115.82% and a negative return on equity of 20.10%. The company’s quarterly revenue was down 91.0% on a year-over-year basis. During the same quarter last year, the business earned $0.19 earnings per share. On average, research analysts expect that Moderna will post -7.47 EPS for the current year.

Insider Activity at Moderna

In related news, CFO James M. Mock sold 647 shares of the firm’s stock in a transaction that occurred on Thursday, February 29th. The shares were sold at an average price of $94.57, for a total value of $61,186.79. Following the sale, the chief financial officer now directly owns 4,300 shares of the company’s stock, valued at $406,651. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, CFO James M. Mock sold 647 shares of the business’s stock in a transaction that occurred on Thursday, February 29th. The shares were sold at an average price of $94.57, for a total value of $61,186.79. Following the completion of the sale, the chief financial officer now directly owns 4,300 shares in the company, valued at approximately $406,651. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, President Stephen Hoge sold 2,388 shares of the business’s stock in a transaction that occurred on Thursday, February 29th. The stock was sold at an average price of $94.57, for a total transaction of $225,833.16. Following the completion of the sale, the president now owns 1,515,898 shares of the company’s stock, valued at $143,358,473.86. The disclosure for this sale can be found here. Insiders have sold 139,954 shares of company stock valued at $14,822,576 over the last three months. 15.20% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Moderna

A number of hedge funds have recently made changes to their positions in MRNA. Allworth Financial LP increased its stake in shares of Moderna by 6.5% in the fourth quarter. Allworth Financial LP now owns 1,660 shares of the company’s stock worth $165,000 after buying an additional 101 shares during the period. TIAA Trust National Association increased its stake in shares of Moderna by 2.3% in the fourth quarter. TIAA Trust National Association now owns 4,491 shares of the company’s stock worth $447,000 after buying an additional 102 shares during the period. Principle Wealth Partners LLC increased its stake in shares of Moderna by 4.3% in the first quarter. Principle Wealth Partners LLC now owns 2,497 shares of the company’s stock worth $266,000 after buying an additional 102 shares during the period. Sound Income Strategies LLC increased its stake in shares of Moderna by 17.8% in the fourth quarter. Sound Income Strategies LLC now owns 762 shares of the company’s stock worth $76,000 after buying an additional 115 shares during the period. Finally, EverSource Wealth Advisors LLC increased its stake in shares of Moderna by 32.3% in the fourth quarter. EverSource Wealth Advisors LLC now owns 475 shares of the company’s stock worth $47,000 after buying an additional 116 shares during the period. 75.33% of the stock is currently owned by institutional investors.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.